Table 3.
Clinical characteristics of EZH2 expression in hepatocellular carcinoma.
| EZH2 Expression | |||
|---|---|---|---|
| High (%, n) | Low (%, n) | p Value | |
| Age | 0.027 * | ||
| <65 | 56.0 (98) | 44.0 (77) | |
| ≥65 | 44.3 (82) | 55.7 (103) | |
| Sex | 0.176 | ||
| Male | 47.5 (116) | 52.5 (128) | |
| Female | 55.2 (64) | 44.8 (52) | |
| T stage | 0.386 | ||
| T1 | 51.4 (90) | 48.6 (85) | |
| T2 | 43.0 (40) | 57.0 (53) | |
| T3 | 56.0 (42) | 44.0 (33) | |
| T4 | 50 (7) | 50 (7) | |
| N stage | 0.045 * | ||
| N0 | 49.4 (117) | 50.6 (120) | |
| N1 | 100 (4) | 0 (0) | |
| M stage | 0.614 | ||
| M0 | 51.4 (129) | 48.6 (122) | |
| M1 | 40.0 (2) | 60.0 (3) | |
| AFP | <0.001 * | ||
| <20 ng/mL | 34.9 (51) | 65.1 (95) | |
| ≥20 ng/mL | 65.9 (85) | 34.1 (44) | |
| Child–Pugh class | 0.543 | ||
| A | 44.9 (97) | 55.1 (119) | |
| B | 45.0 (9) | 55.0 (11) | |
| C | 100 (1) | 0 (0) | |
* p < 0.05.